{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:33:36Z","timestamp":1781825616879,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40292-020-00399-6","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T10:03:41Z","timestamp":1594375421000},"page":"331-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7913-1526","authenticated-orcid":false,"given":"Lindsay E.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-918X","authenticated-orcid":false,"given":"Elizabeth K.","family":"Pogge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"issue":"25","key":"399_CR1","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation."},{"issue":"4","key":"399_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.mayocp.2018.08.011","volume":"94","author":"R Cardoso","year":"2019","unstructured":"Cardoso R, Blumenthal RS, Kopecky S, et al. How low to go with lipid-lowering therapies in a cost-effective and prudent manner. Mayo Clin Proc. 2019;94(4):660\u20139.","journal-title":"Mayo Clin Proc."},{"issue":"14","key":"399_CR3","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update on the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785\u2013822.","journal-title":"J Am Coll Cardiol."},{"key":"399_CR4","unstructured":"Repatha\u00ae [package insert]. Thousand Oaks, CA: Amgen Inc; 2019."},{"key":"399_CR5","unstructured":"Praluent\u00ae [package insert]. Bridgewater, NJ: Sanofi-aventis U.S. LLC; 2019."},{"issue":"18","key":"399_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giufliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New Engl J Med. 2017;376(18):1713\u201322.","journal-title":"New Engl J Med."},{"issue":"22","key":"399_CR7","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szerek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. New Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"New Engl J Med."},{"issue":"4","key":"399_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jacl.2017.05.001","volume":"11","author":"CE Orringer","year":"2017","unstructured":"Orringer CE, Jacobson TA, Saseen JJ, et al. Update on the use of PCSK9 inhibitors in adults: recommendations from an expert panel of the National Lipid Association. J Clin Lipidol. 2017;11(4):880\u201390.","journal-title":"J Clin Lipidol."},{"issue":"14","key":"399_CR9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","volume":"39","author":"U Landmesser","year":"2018","unstructured":"Landmesser U, Chapman MJ, Stock JK, et al. 2017 update on ESC\/EAS task force on practical clinical guidance for proprotein covertase subtilisin\/kexin type 9 inhibitor in patients with atherosclerotic cardiovascular disease or familial hypercholesterolaemia. Eur Heart J. 2018;39(14):1131\u201343.","journal-title":"Eur Heart J."},{"issue":"S1","key":"399_CR10","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3909\/ricm19S1S0002","volume":"19","author":"EM Roth","year":"2018","unstructured":"Roth EM, Davidson MH. PCSK9 Inhibitors: Mechanism of action, efficacy, and safety. Rev Cardiovasc Med. 2018;19(S1):S31\u201346.","journal-title":"Rev Cardiovasc Med."},{"key":"399_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40292-019-00323-7","volume":"26","author":"R Del Pinto","year":"2019","unstructured":"Del Pinto R, Grassi D, Properzi G, et al. Low density lipoprotein (LDL) cholesterol as a causal role for atherosclerotic disease: potential role of PCSK9 inhibitors. High Blood Press Cardiovasc Prev. 2019;26:199\u2013207.","journal-title":"High Blood Press Cardiovasc Prev."},{"key":"399_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40292-019-00356-y","volume":"27","author":"D D\u2019Ardes","year":"2020","unstructured":"D\u2019Ardes D, Santilli F, Guagnano M, et al. From endothelium to lipids, through microRNAs and PCSK9: a fascinating travel across atherosclerosis. High Blood Press Cardiovasc Prev. 2020;27:1\u20138.","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"1","key":"399_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14728214.2019.1591372","volume":"24","author":"M Bove","year":"2019","unstructured":"Bove M, Cicero AFG, Borghi C. Emerging drugs for the treatment of hypercholesterolemia. Expert Opin Emerg Drugs. 2019;24(1):63\u20139.","journal-title":"Expert Opin Emerg Drugs."},{"issue":"7","key":"399_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.2016.11004","volume":"316","author":"DS Kazi","year":"2016","unstructured":"Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316(7):743\u201353.","journal-title":"JAMA."},{"key":"399_CR15","unstructured":"Slevin G, Silas J. Cost-sharing: What\u2019s the difference between \u201cco-payment\u201d and \u201cco-insurance\u201d? In: Consumer Union. 2015. https:\/\/advocacy.consumerreports.org\/wp-content\/uploads\/2015\/10\/Coinsurance_FAQs_National_October2015.pdf. Accessed 12 June 2020."},{"key":"399_CR16","unstructured":"Dangi-Garimella S. Amgen announces 60% reduction in list price of PCSK9 inhibitor evolocumab. In: Amer J Managed Care. 2018. https:\/\/www.ajmc.com\/newsroom\/amgen-announces-60-reduction-in-list-price-of-pcsk9-inhibitor-evolocumab. Accessed 12 June 2020."},{"issue":"4","key":"399_CR17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jacl.2017.04.120","volume":"11","author":"JD Cohen","year":"2017","unstructured":"Cohen JD, Cziraky MJ, Jacobson TA, et al. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: results of a healthcare provider survey conducted by the National Lipid Association. J Clin Lipidol. 2017;11(4):891\u2013900.","journal-title":"J Clin Lipidol."},{"issue":"6","key":"399_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40256-019-00352-6","volume":"19","author":"JJ Maciejko","year":"2019","unstructured":"Maciejko JJ, Jamoua R, Anne P. Assessment and management of patients with hyperlipidemia referred for initiation of PCSK9 inhibitor therapy: a lipid clinic experience. Am J Cardiovasc Drugs. 2019;19(6):553\u20139.","journal-title":"Am J Cardiovasc Drugs."},{"key":"399_CR19","doi-asserted-by":"crossref","unstructured":"Davidson ER, Snider MJ, Bartsch K, et al. Tolerance of Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in patients with self-reported statin intolerance. J Pharm Pract. 2018; 897190018799218.","DOI":"10.1177\/0897190018799218"},{"issue":"1","key":"399_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/CIRCRESAHA.118.314191","volume":"124","author":"TM Kaufman","year":"2019","unstructured":"Kaufman TM, Warden BA, Minnier J, et al. Application of PCSK9 inhibitors in practice. Circ Res. 2019;124(1):32\u20137.","journal-title":"Circ Res."},{"issue":"2","key":"399_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40266-014-0238-5","volume":"32","author":"Y Weinberger","year":"2015","unstructured":"Weinberger Y, Han BH. Statin treatment for older adults: the impact of the 2013 ACC\/AHA cholesterol guidelines. Drugs Aging. 2015;32(2):87\u201393.","journal-title":"Drugs Aging."},{"key":"399_CR22","doi-asserted-by":"publisher","DOI":"10.1089\/rej.2019.2268","author":"G Viscogliosi","year":"2020","unstructured":"Viscogliosi G, Donfrancesco C, Lo Noce C, et al. Prevalence and correlates of statin underuse for secondary prevention of cardiovascular disease in older adults 65\u201379 years of age: the Italian Health Examination Survey 2008\u20132012. Rejuvenation Res. 2020. https:\/\/doi.org\/10.1089\/rej.2019.2268.","journal-title":"Rejuvenation Res."},{"issue":"10","key":"399_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3928\/00989134-20120911-04","volume":"38","author":"K McLain","year":"2012","unstructured":"McLain K, Edlund BJ. Statin drugs: reducing cardiovascular risk in older adults. J Gerontol Nurs. 2012;38(10):9\u201313.","journal-title":"J Gerontol Nurs."},{"key":"399_CR24","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1161\/CIRCULATIONAHA.117.028430","volume":"136","author":"GP Hess","year":"2017","unstructured":"Hess GP, Natarajan P, Faridi KF, et al. Proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing. Circulation. 2017;136:2210\u20139.","journal-title":"Circulation."},{"issue":"6","key":"399_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758\u201369.","journal-title":"J Clin Lipidol."},{"issue":"15","key":"399_CR26","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580\u201390.","journal-title":"JAMA."},{"key":"399_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.phrs.2017.04.008","volume":"120","author":"TP Johnston","year":"2017","unstructured":"Johnston TP, Korolenko TA, Pirro M, et al. Preventing cardiovascular heart disease: promising nutraceutical and non-nutraceutical treatments for cholesterol management. Pharmacol Res. 2017;120:219\u201325.","journal-title":"Pharmacol Res."},{"key":"399_CR28","doi-asserted-by":"publisher","first-page":"106566","DOI":"10.1016\/j.vph.2019.106566","volume":"120","author":"A Dressel","year":"2019","unstructured":"Dressel A, Schmidt B, Schmidt N, et al. Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: insights from the Ludwigshafen risk and cardiovascular health cohort. Vascul Pharmacol. 2019;120:106566.","journal-title":"Vascul Pharmacol."}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-020-00399-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-020-00399-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-020-00399-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T07:08:34Z","timestamp":1667372914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-020-00399-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1007\/s40292-020-00399-6","relation":{},"ISSN":["1120-9879","1179-1985"],"issn-type":[{"value":"1120-9879","type":"print"},{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Lindsay Davis and Elizabeth Pogge declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived by the local Ethics Committee at Midwestern University in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}